1. Is metformin still the most efficacious first‐line oral hypoglycaemic drug in treating type 2 diabetes? A network meta‐analysis of randomized controlled trials.
- Author
-
Jia, Y., Lao, Y., Zhu, H., Li, N., and Leung, S.‐W.
- Subjects
METFORMIN ,TYPE 2 diabetes treatment ,DRUG efficacy ,META-analysis ,RANDOMIZED controlled trials - Abstract
Summary: Objectives: The objective of the study is to compare the efficacy of hypoglycaemic drugs for type 2 diabetes mellitus (T2DM) by network meta‐analysis of randomized controlled trials (RCTs). Methods: We compared 11 major oral hypoglycaemic drugs under five categories evaluated by RCTs as drug monotherapy for the patients with T2DM, measuring glycosylated haemoglobin (%) or fasting plasma glucose (mmol L−1) as outcomes. RCT quality was assessed with the Cochrane risk of bias tool. Network meta‐analysis estimated the mean differences and 95% credible intervals. Subgroup and sensitivity analyses were performed to determine the results robustness. The Grading of Recommendation, Assessment, Development, and Evaluation evidence strength was assessed. Results: Seventy‐five RCTs including 33,830 patients were identified. Their study quality was high. Regarding glycosylated haemoglobin, top three anti‐diabetics were repaglinide (mean differences −1.39 [95% credible intervals −1.75 to −1.03]), gliclazide (−1.37 [−2.04 to −0.71]) and metformin (−1.13 [−1.37 to −0.90]), against placebo. Regarding fasting plasma glucose, top three anti‐diabetics were repaglinide (−2.01 [−2.75 to −0.97]), metformin (−1.72 [−2.16 to −1.27]) and glipizide (−1.57 [−2.44 to −0.64]), against placebo. There was no difference between metformin and repaglinide. Subgroup and sensitivity analyses found the results to be robust. The evidence strength was moderate to high. Conclusion: This meta‐analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first‐line monotherapy of T2DM. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF